Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 50 | 2021 | 5315 | 2.180 |
Why?
|
Lung Neoplasms | 68 | 2023 | 13380 | 1.990 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 51 | 2021 | 11742 | 0.850 |
Why?
|
Small Cell Lung Carcinoma | 9 | 2020 | 423 | 0.840 |
Why?
|
Bronchopulmonary Dysplasia | 4 | 2024 | 326 | 0.680 |
Why?
|
Endpoint Determination | 3 | 2018 | 590 | 0.650 |
Why?
|
Thoracic Neoplasms | 2 | 2020 | 267 | 0.630 |
Why?
|
Clinical Trials as Topic | 20 | 2020 | 8002 | 0.600 |
Why?
|
Data Interpretation, Statistical | 2 | 2018 | 2691 | 0.550 |
Why?
|
Carboplatin | 14 | 2021 | 794 | 0.460 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2014 | 1551 | 0.460 |
Why?
|
Protein Kinase Inhibitors | 17 | 2023 | 5671 | 0.460 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2014 | 326 | 0.410 |
Why?
|
Biostatistics | 1 | 2014 | 164 | 0.410 |
Why?
|
Cancer Care Facilities | 3 | 2014 | 422 | 0.400 |
Why?
|
Research Design | 8 | 2018 | 6180 | 0.390 |
Why?
|
Quinazolines | 4 | 2016 | 1371 | 0.370 |
Why?
|
Sample Size | 1 | 2014 | 841 | 0.370 |
Why?
|
Antineoplastic Agents | 17 | 2020 | 13639 | 0.370 |
Why?
|
Asparaginase | 4 | 2014 | 240 | 0.360 |
Why?
|
Adenocarcinoma | 11 | 2016 | 6346 | 0.350 |
Why?
|
Metformin | 1 | 2018 | 906 | 0.350 |
Why?
|
Paclitaxel | 12 | 2019 | 1732 | 0.350 |
Why?
|
Prednisone | 19 | 2019 | 1563 | 0.330 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 5 | 2016 | 1745 | 0.310 |
Why?
|
Lymphoma, Non-Hodgkin | 16 | 1999 | 1374 | 0.300 |
Why?
|
Cisplatin | 13 | 2021 | 1651 | 0.300 |
Why?
|
Mutation | 21 | 2023 | 30052 | 0.280 |
Why?
|
Neoplasm Staging | 29 | 2019 | 11121 | 0.280 |
Why?
|
Acrylamides | 2 | 2019 | 260 | 0.280 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2019 | 4026 | 0.280 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2011 | 382 | 0.270 |
Why?
|
Etoposide | 15 | 2020 | 634 | 0.270 |
Why?
|
Spirometry | 3 | 2024 | 929 | 0.270 |
Why?
|
Survival Analysis | 22 | 2020 | 10090 | 0.260 |
Why?
|
Doxorubicin | 19 | 2014 | 2224 | 0.260 |
Why?
|
Humans | 168 | 2024 | 761504 | 0.250 |
Why?
|
Survival Rate | 26 | 2019 | 12725 | 0.250 |
Why?
|
Disease-Free Survival | 18 | 2019 | 6814 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-met | 4 | 2019 | 571 | 0.230 |
Why?
|
Oscillometry | 1 | 2024 | 150 | 0.220 |
Why?
|
Proxy | 1 | 2024 | 151 | 0.220 |
Why?
|
Aniline Compounds | 2 | 2019 | 1069 | 0.220 |
Why?
|
Aged, 80 and over | 44 | 2021 | 58976 | 0.220 |
Why?
|
Antibiotics, Antineoplastic | 5 | 2012 | 678 | 0.220 |
Why?
|
Cystic Fibrosis | 2 | 2022 | 1285 | 0.210 |
Why?
|
Lung Transplantation | 2 | 2024 | 1310 | 0.210 |
Why?
|
Aged | 78 | 2021 | 169289 | 0.210 |
Why?
|
Smoke | 1 | 2024 | 235 | 0.210 |
Why?
|
Neoplasms | 7 | 2022 | 22170 | 0.210 |
Why?
|
Mesothelioma | 2 | 2019 | 807 | 0.210 |
Why?
|
Female | 111 | 2024 | 392644 | 0.210 |
Why?
|
Parents | 4 | 2024 | 3563 | 0.200 |
Why?
|
Middle Aged | 89 | 2023 | 220895 | 0.200 |
Why?
|
Pulmonary Medicine | 1 | 2024 | 221 | 0.190 |
Why?
|
Gastroparesis | 1 | 2024 | 136 | 0.190 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2012 | 89 | 0.190 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2021 | 110 | 0.190 |
Why?
|
Tumor Burden | 6 | 2020 | 1893 | 0.190 |
Why?
|
Male | 101 | 2024 | 360804 | 0.190 |
Why?
|
Pregnancy in Adolescence | 1 | 2022 | 163 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2014 | 9280 | 0.180 |
Why?
|
Adolescent Health Services | 1 | 2022 | 218 | 0.180 |
Why?
|
ras-GRF1 | 1 | 2020 | 26 | 0.180 |
Why?
|
Carcinoma, Small Cell | 4 | 2014 | 420 | 0.170 |
Why?
|
Bullying | 1 | 2023 | 232 | 0.170 |
Why?
|
Proportional Hazards Models | 11 | 2019 | 12463 | 0.170 |
Why?
|
Pregnancy Rate | 1 | 2022 | 648 | 0.170 |
Why?
|
Ovarian Diseases | 1 | 2020 | 137 | 0.170 |
Why?
|
Benzeneacetamides | 1 | 2019 | 36 | 0.170 |
Why?
|
Vascular Surgical Procedures | 4 | 2013 | 1489 | 0.160 |
Why?
|
Prognosis | 25 | 2019 | 29625 | 0.160 |
Why?
|
Adult | 75 | 2023 | 221177 | 0.160 |
Why?
|
Cohort Studies | 7 | 2018 | 41487 | 0.160 |
Why?
|
Treatment Outcome | 31 | 2020 | 64680 | 0.160 |
Why?
|
Receptor, erbB-2 | 4 | 2020 | 2557 | 0.150 |
Why?
|
Anti-Mullerian Hormone | 1 | 2020 | 407 | 0.150 |
Why?
|
Leg | 2 | 2013 | 1088 | 0.150 |
Why?
|
Liver Neoplasms | 1 | 2013 | 4320 | 0.150 |
Why?
|
Neoplasms, Glandular and Epithelial | 2 | 2013 | 487 | 0.140 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2020 | 3639 | 0.140 |
Why?
|
Angioplasty, Balloon | 2 | 2013 | 589 | 0.140 |
Why?
|
Antibodies, Monoclonal | 10 | 2021 | 9177 | 0.140 |
Why?
|
Carcinoma, Large Cell | 3 | 2013 | 113 | 0.140 |
Why?
|
Air Pollution, Indoor | 1 | 2024 | 901 | 0.140 |
Why?
|
Amenorrhea | 1 | 2020 | 483 | 0.140 |
Why?
|
Neurofibromin 1 | 2 | 2016 | 190 | 0.140 |
Why?
|
Cholecalciferol | 1 | 2022 | 553 | 0.140 |
Why?
|
Anilides | 2 | 2016 | 411 | 0.140 |
Why?
|
Adrenal Cortex Hormones | 2 | 2019 | 1880 | 0.140 |
Why?
|
Drug Evaluation | 7 | 1992 | 641 | 0.140 |
Why?
|
Interviews as Topic | 1 | 2024 | 2696 | 0.130 |
Why?
|
Precancerous Conditions | 1 | 2023 | 980 | 0.130 |
Why?
|
Gastroesophageal Reflux | 1 | 2024 | 819 | 0.130 |
Why?
|
Campylobacter Infections | 1 | 2016 | 31 | 0.130 |
Why?
|
Campylobacter | 1 | 2016 | 57 | 0.130 |
Why?
|
Polymerase Chain Reaction | 3 | 2016 | 6075 | 0.130 |
Why?
|
Retrospective Studies | 23 | 2024 | 80636 | 0.130 |
Why?
|
Vincristine | 15 | 2014 | 1036 | 0.130 |
Why?
|
Food Hypersensitivity | 1 | 2023 | 729 | 0.120 |
Why?
|
Fellowships and Scholarships | 1 | 2024 | 1117 | 0.120 |
Why?
|
Gastrointestinal Diseases | 1 | 2024 | 1200 | 0.120 |
Why?
|
Peripheral Vascular Diseases | 2 | 2008 | 488 | 0.120 |
Why?
|
Razoxane | 2 | 2012 | 43 | 0.120 |
Why?
|
Bacteriological Techniques | 1 | 2016 | 275 | 0.120 |
Why?
|
Exons | 3 | 2019 | 2391 | 0.120 |
Why?
|
Ischemia | 2 | 2013 | 1882 | 0.120 |
Why?
|
PTEN Phosphohydrolase | 2 | 2011 | 1115 | 0.120 |
Why?
|
Bone Marrow Transplantation | 10 | 2000 | 2693 | 0.120 |
Why?
|
Remission Induction | 12 | 2016 | 2396 | 0.120 |
Why?
|
DNA, Neoplasm | 2 | 2016 | 1745 | 0.110 |
Why?
|
Risk Assessment | 7 | 2013 | 23995 | 0.110 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2019 | 5305 | 0.110 |
Why?
|
Breast Neoplasms | 4 | 2023 | 21012 | 0.110 |
Why?
|
Drug Administration Schedule | 12 | 2017 | 4853 | 0.110 |
Why?
|
Child | 29 | 2024 | 80153 | 0.110 |
Why?
|
Follow-Up Studies | 20 | 2019 | 39106 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2016 | 1626 | 0.110 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2013 | 1520 | 0.110 |
Why?
|
Obesity | 2 | 2013 | 12947 | 0.110 |
Why?
|
Gene Deletion | 2 | 2011 | 2665 | 0.110 |
Why?
|
Self Report | 1 | 2024 | 3724 | 0.110 |
Why?
|
Menstrual Cycle | 1 | 2006 | 539 | 0.110 |
Why?
|
Cardiotoxins | 1 | 2012 | 36 | 0.110 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2015 | 857 | 0.110 |
Why?
|
Hypertension, Pulmonary | 1 | 2024 | 1578 | 0.100 |
Why?
|
Isotretinoin | 1 | 2014 | 134 | 0.100 |
Why?
|
Lower Extremity | 2 | 2013 | 1202 | 0.100 |
Why?
|
Particulate Matter | 1 | 2024 | 2605 | 0.100 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2016 | 946 | 0.100 |
Why?
|
Planning Techniques | 1 | 1992 | 82 | 0.100 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2012 | 74 | 0.100 |
Why?
|
Peripheral Arterial Disease | 2 | 2013 | 1273 | 0.100 |
Why?
|
Comparative Genomic Hybridization | 2 | 2010 | 473 | 0.100 |
Why?
|
Pyridines | 4 | 2016 | 2875 | 0.100 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2020 | 1606 | 0.100 |
Why?
|
Thiazoles | 1 | 2019 | 1517 | 0.100 |
Why?
|
Cyclophosphamide | 17 | 1998 | 2218 | 0.100 |
Why?
|
Disease Progression | 10 | 2019 | 13506 | 0.100 |
Why?
|
Autocrine Communication | 1 | 2012 | 169 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2011 | 2455 | 0.100 |
Why?
|
Anorexia Nervosa | 1 | 2020 | 1361 | 0.100 |
Why?
|
NAD(P)H Dehydrogenase (Quinone) | 1 | 2011 | 56 | 0.090 |
Why?
|
Intermittent Claudication | 1 | 2013 | 304 | 0.090 |
Why?
|
Sulfotransferases | 1 | 2011 | 150 | 0.090 |
Why?
|
Dexamethasone | 7 | 2013 | 1948 | 0.090 |
Why?
|
Genes, T-Cell Receptor gamma | 1 | 2010 | 15 | 0.090 |
Why?
|
Adolescent | 33 | 2024 | 88319 | 0.090 |
Why?
|
Air Pollutants | 1 | 2024 | 2896 | 0.090 |
Why?
|
Hypertension | 2 | 2010 | 8540 | 0.090 |
Why?
|
Ubiquitins | 1 | 2011 | 366 | 0.090 |
Why?
|
Angioplasty | 1 | 2013 | 355 | 0.090 |
Why?
|
Mutagenesis, Insertional | 1 | 2013 | 656 | 0.090 |
Why?
|
Diagnostic Tests, Routine | 1 | 2016 | 787 | 0.090 |
Why?
|
Program Evaluation | 1 | 2018 | 2495 | 0.090 |
Why?
|
Prospective Studies | 15 | 2024 | 54425 | 0.090 |
Why?
|
Interferon-alpha | 1 | 2014 | 921 | 0.080 |
Why?
|
Hodgkin Disease | 4 | 2008 | 1378 | 0.080 |
Why?
|
Lymphoid Enhancer-Binding Factor 1 | 1 | 2010 | 84 | 0.080 |
Why?
|
Codon, Terminator | 1 | 2010 | 124 | 0.080 |
Why?
|
Immunotherapy | 5 | 2019 | 4652 | 0.080 |
Why?
|
Air Pollution | 1 | 2023 | 2359 | 0.080 |
Why?
|
Octreotide | 1 | 2010 | 153 | 0.080 |
Why?
|
Haploinsufficiency | 1 | 2011 | 337 | 0.080 |
Why?
|
Fatigue | 4 | 2023 | 1552 | 0.080 |
Why?
|
Feces | 1 | 2016 | 1497 | 0.080 |
Why?
|
Smoking Cessation | 1 | 2021 | 2056 | 0.080 |
Why?
|
Bone Density | 1 | 2022 | 3551 | 0.080 |
Why?
|
Child, Preschool | 18 | 2024 | 42230 | 0.080 |
Why?
|
Decision Making | 2 | 2021 | 3929 | 0.080 |
Why?
|
Pediatrics | 1 | 2024 | 3589 | 0.080 |
Why?
|
Cardiotonic Agents | 1 | 2012 | 539 | 0.080 |
Why?
|
Benzimidazoles | 3 | 2020 | 858 | 0.080 |
Why?
|
Immunohistochemistry | 7 | 2018 | 11076 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 6 | 2017 | 6484 | 0.080 |
Why?
|
Quality of Life | 3 | 2024 | 13367 | 0.080 |
Why?
|
Behavior | 1 | 2011 | 541 | 0.080 |
Why?
|
Biomedical Research | 1 | 2023 | 3429 | 0.070 |
Why?
|
Drug Industry | 1 | 2014 | 788 | 0.070 |
Why?
|
Oncogenes | 1 | 2013 | 1222 | 0.070 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2019 | 297 | 0.070 |
Why?
|
HLA Antigens | 5 | 2000 | 1328 | 0.070 |
Why?
|
Thymus Neoplasms | 1 | 2010 | 274 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 1405 | 0.070 |
Why?
|
Lymphoma, Follicular | 1 | 2011 | 457 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2017 | 3514 | 0.070 |
Why?
|
Embryonic Development | 1 | 2012 | 721 | 0.070 |
Why?
|
Lung | 5 | 2024 | 10000 | 0.070 |
Why?
|
Molecular Targeted Therapy | 2 | 2015 | 2811 | 0.070 |
Why?
|
Neurofibromatosis 1 | 1 | 2012 | 561 | 0.070 |
Why?
|
Adhesins, Bacterial | 1 | 2007 | 118 | 0.070 |
Why?
|
Fimbriae Proteins | 1 | 2007 | 132 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 2 | 2021 | 2803 | 0.070 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2022 | 2422 | 0.070 |
Why?
|
Cytarabine | 7 | 2014 | 697 | 0.070 |
Why?
|
Troponin T | 1 | 2012 | 780 | 0.070 |
Why?
|
Cell Proliferation | 4 | 2020 | 10445 | 0.070 |
Why?
|
Aortic Rupture | 1 | 2009 | 319 | 0.070 |
Why?
|
Thalidomide | 1 | 2012 | 885 | 0.070 |
Why?
|
Methotrexate | 10 | 2014 | 1719 | 0.070 |
Why?
|
Age Factors | 11 | 2016 | 18395 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2010 | 727 | 0.070 |
Why?
|
Continuity of Patient Care | 1 | 2013 | 1069 | 0.070 |
Why?
|
Bacterial Adhesion | 1 | 2007 | 306 | 0.070 |
Why?
|
Autoimmune Diseases | 1 | 2018 | 2244 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2011 | 988 | 0.060 |
Why?
|
Mutation, Missense | 2 | 2013 | 2571 | 0.060 |
Why?
|
Bleomycin | 9 | 1994 | 494 | 0.060 |
Why?
|
Saphenous Vein | 1 | 2008 | 516 | 0.060 |
Why?
|
Sequence Deletion | 1 | 2010 | 1494 | 0.060 |
Why?
|
Graft Occlusion, Vascular | 1 | 2008 | 537 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 3530 | 0.060 |
Why?
|
Smoking | 3 | 2021 | 9053 | 0.060 |
Why?
|
Neoplasm Metastasis | 4 | 2019 | 4915 | 0.060 |
Why?
|
Burkitt Lymphoma | 1 | 2007 | 335 | 0.060 |
Why?
|
Time Factors | 13 | 2013 | 39967 | 0.060 |
Why?
|
Heart Ventricles | 2 | 2012 | 3807 | 0.060 |
Why?
|
Risk Factors | 13 | 2024 | 74206 | 0.060 |
Why?
|
Germ-Line Mutation | 2 | 2023 | 1858 | 0.060 |
Why?
|
Palliative Care | 1 | 2019 | 3598 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2013 | 2865 | 0.060 |
Why?
|
Zebrafish | 2 | 2012 | 3007 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2014 | 2759 | 0.060 |
Why?
|
Cardiomyopathies | 2 | 2012 | 1964 | 0.060 |
Why?
|
Ventricular Function, Left | 3 | 2012 | 3879 | 0.060 |
Why?
|
Volatile Organic Compounds | 1 | 2024 | 86 | 0.050 |
Why?
|
Camptothecin | 3 | 2013 | 591 | 0.050 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 1993 | 1405 | 0.050 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2012 | 1723 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2020 | 7856 | 0.050 |
Why?
|
Young Adult | 10 | 2022 | 59243 | 0.050 |
Why?
|
Genotype | 5 | 2016 | 12990 | 0.050 |
Why?
|
Echocardiography | 2 | 2012 | 4989 | 0.050 |
Why?
|
Topotecan | 2 | 2013 | 132 | 0.050 |
Why?
|
Models, Statistical | 2 | 2006 | 5079 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 5 | 2020 | 20570 | 0.050 |
Why?
|
Treatment Failure | 4 | 2015 | 2645 | 0.050 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2012 | 2825 | 0.050 |
Why?
|
Topoisomerase I Inhibitors | 2 | 2013 | 70 | 0.050 |
Why?
|
Gene Frequency | 5 | 2016 | 3606 | 0.050 |
Why?
|
Pancreatitis | 1 | 2009 | 1096 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 3712 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7390 | 0.050 |
Why?
|
Streptococcus pneumoniae | 1 | 2007 | 730 | 0.050 |
Why?
|
Neoplasm Proteins | 2 | 2010 | 3617 | 0.050 |
Why?
|
Health Status Disparities | 1 | 2013 | 1852 | 0.050 |
Why?
|
Nitrogen Dioxide | 1 | 2024 | 522 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2016 | 14666 | 0.050 |
Why?
|
Massachusetts | 3 | 2024 | 8830 | 0.050 |
Why?
|
Causality | 1 | 2007 | 1242 | 0.050 |
Why?
|
ras Proteins | 2 | 2020 | 1054 | 0.050 |
Why?
|
Vital Capacity | 1 | 2024 | 971 | 0.050 |
Why?
|
Neoplasms, Second Primary | 2 | 2008 | 1052 | 0.050 |
Why?
|
Boston | 1 | 2014 | 9326 | 0.050 |
Why?
|
Arsenicals | 1 | 2001 | 118 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2020 | 3602 | 0.050 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2013 | 2020 | 0.050 |
Why?
|
Pericytes | 1 | 2024 | 293 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2015 | 10209 | 0.050 |
Why?
|
Biometry | 1 | 1984 | 563 | 0.050 |
Why?
|
Hospitals, Urban | 1 | 2022 | 500 | 0.040 |
Why?
|
Sirolimus | 1 | 2007 | 1533 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2011 | 2986 | 0.040 |
Why?
|
Recurrence | 9 | 2011 | 8465 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2011 | 5789 | 0.040 |
Why?
|
Cell Line, Tumor | 5 | 2019 | 16981 | 0.040 |
Why?
|
Infant, Newborn | 5 | 2024 | 26198 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2017 | 10766 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2022 | 5247 | 0.040 |
Why?
|
Pentoxifylline | 1 | 2000 | 53 | 0.040 |
Why?
|
Oxides | 1 | 2001 | 401 | 0.040 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2009 | 1228 | 0.040 |
Why?
|
Brain Neoplasms | 3 | 2019 | 9031 | 0.040 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2001 | 251 | 0.040 |
Why?
|
Family Planning Services | 1 | 2022 | 268 | 0.040 |
Why?
|
Data Collection | 2 | 2011 | 3322 | 0.040 |
Why?
|
Patient Selection | 3 | 2019 | 4244 | 0.040 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2009 | 1428 | 0.040 |
Why?
|
Menogaril | 1 | 1999 | 4 | 0.040 |
Why?
|
Ovarian Neoplasms | 2 | 2013 | 4876 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2012 | 5112 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 3123 | 0.040 |
Why?
|
Forced Expiratory Volume | 1 | 2024 | 1814 | 0.040 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2012 | 3613 | 0.040 |
Why?
|
Chronic Disease | 5 | 2022 | 9318 | 0.040 |
Why?
|
Heart | 1 | 2012 | 4404 | 0.040 |
Why?
|
Research Subjects | 1 | 2020 | 249 | 0.040 |
Why?
|
Radiation Pneumonitis | 1 | 2019 | 102 | 0.040 |
Why?
|
Seasons | 1 | 2024 | 1520 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2021 | 455 | 0.040 |
Why?
|
Infant | 11 | 2016 | 36192 | 0.040 |
Why?
|
Sex Factors | 5 | 2013 | 10552 | 0.040 |
Why?
|
Spheroids, Cellular | 1 | 2020 | 330 | 0.040 |
Why?
|
Environmental Monitoring | 1 | 2024 | 1460 | 0.040 |
Why?
|
Body Mass Index | 2 | 2013 | 12953 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2013 | 3358 | 0.040 |
Why?
|
Limb Salvage | 2 | 2013 | 481 | 0.040 |
Why?
|
Allosteric Regulation | 1 | 2019 | 426 | 0.040 |
Why?
|
Placebos | 2 | 2018 | 1667 | 0.040 |
Why?
|
Venous Thromboembolism | 1 | 2011 | 1866 | 0.040 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2012 | 651 | 0.040 |
Why?
|
NIH 3T3 Cells | 1 | 2019 | 670 | 0.040 |
Why?
|
Logistic Models | 4 | 2016 | 13255 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2022 | 20098 | 0.030 |
Why?
|
Cyclosporins | 2 | 1988 | 216 | 0.030 |
Why?
|
Signal Transduction | 4 | 2016 | 23445 | 0.030 |
Why?
|
Radionuclide Ventriculography | 1 | 1996 | 40 | 0.030 |
Why?
|
Cytokines | 1 | 2011 | 7396 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2019 | 4740 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2016 | 2425 | 0.030 |
Why?
|
Thrombocytopenia | 4 | 2015 | 1181 | 0.030 |
Why?
|
Thallium Radioisotopes | 1 | 1996 | 138 | 0.030 |
Why?
|
Graft vs Host Disease | 5 | 2000 | 3029 | 0.030 |
Why?
|
Dipyridamole | 1 | 1996 | 140 | 0.030 |
Why?
|
Cell Survival | 2 | 2019 | 5791 | 0.030 |
Why?
|
Absorptiometry, Photon | 1 | 2022 | 1738 | 0.030 |
Why?
|
Water | 1 | 2022 | 1411 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 4575 | 0.030 |
Why?
|
Mice | 6 | 2024 | 81525 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1827 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2011 | 8547 | 0.030 |
Why?
|
RNA, Viral | 1 | 2023 | 2846 | 0.030 |
Why?
|
Bone Marrow | 3 | 2022 | 2911 | 0.030 |
Why?
|
Vascular Patency | 2 | 2008 | 911 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2626 | 0.030 |
Why?
|
Leucovorin | 6 | 1994 | 643 | 0.030 |
Why?
|
DNA Mutational Analysis | 2 | 2013 | 4111 | 0.030 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2020 | 710 | 0.030 |
Why?
|
Lymphoma | 3 | 1990 | 1901 | 0.030 |
Why?
|
Pleural Neoplasms | 1 | 2019 | 609 | 0.030 |
Why?
|
Quinolines | 1 | 2020 | 764 | 0.030 |
Why?
|
Multivariate Analysis | 5 | 2013 | 12059 | 0.030 |
Why?
|
Predictive Value of Tests | 4 | 2016 | 15266 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2014 | 69 | 0.030 |
Why?
|
Blood Pressure | 1 | 2010 | 8481 | 0.030 |
Why?
|
Incidence | 3 | 2024 | 21353 | 0.030 |
Why?
|
Immune System | 1 | 2019 | 796 | 0.030 |
Why?
|
Leukopenia | 1 | 2014 | 213 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2016 | 2917 | 0.030 |
Why?
|
Pyrazoles | 2 | 2016 | 2009 | 0.030 |
Why?
|
Animals | 8 | 2024 | 168459 | 0.030 |
Why?
|
United States | 8 | 2019 | 72334 | 0.030 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2013 | 94 | 0.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2011 | 5671 | 0.030 |
Why?
|
Vitamins | 1 | 2022 | 1635 | 0.030 |
Why?
|
Lymphoid Tissue | 1 | 1995 | 445 | 0.030 |
Why?
|
Base Sequence | 2 | 2016 | 12441 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2020 | 1486 | 0.030 |
Why?
|
Tablets | 1 | 2013 | 148 | 0.030 |
Why?
|
Capsules | 1 | 2013 | 191 | 0.030 |
Why?
|
Anemia, Aplastic | 2 | 1986 | 230 | 0.030 |
Why?
|
Melanophores | 1 | 2012 | 16 | 0.030 |
Why?
|
Genes, erbB-1 | 1 | 2013 | 162 | 0.030 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2013 | 95 | 0.030 |
Why?
|
Lumbar Vertebrae | 1 | 2022 | 1879 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2015 | 629 | 0.030 |
Why?
|
Karyotyping | 1 | 2014 | 1171 | 0.030 |
Why?
|
Immunoassay | 1 | 2016 | 745 | 0.030 |
Why?
|
DNA Repair | 1 | 2021 | 2045 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6132 | 0.020 |
Why?
|
Vitamin D Deficiency | 1 | 2022 | 1388 | 0.020 |
Why?
|
Sulfatases | 1 | 2011 | 44 | 0.020 |
Why?
|
Radiotherapy | 3 | 2011 | 1499 | 0.020 |
Why?
|
Whole-Body Irradiation | 4 | 2000 | 433 | 0.020 |
Why?
|
Blotting, Western | 2 | 2011 | 5035 | 0.020 |
Why?
|
Cryoultramicrotomy | 1 | 2011 | 16 | 0.020 |
Why?
|
Gastric Mucosa | 1 | 1995 | 604 | 0.020 |
Why?
|
Patient Participation | 1 | 2021 | 1444 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2024 | 2373 | 0.020 |
Why?
|
Combined Modality Therapy | 6 | 2011 | 8529 | 0.020 |
Why?
|
Observer Variation | 1 | 2018 | 2606 | 0.020 |
Why?
|
Endocardium | 1 | 1992 | 248 | 0.020 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2011 | 106 | 0.020 |
Why?
|
Schwann Cells | 1 | 2012 | 197 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 15936 | 0.020 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2012 | 257 | 0.020 |
Why?
|
Arabinonucleotides | 1 | 1990 | 5 | 0.020 |
Why?
|
Vidarabine Phosphate | 1 | 1990 | 11 | 0.020 |
Why?
|
Internationality | 1 | 2006 | 1001 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2024 | 3548 | 0.020 |
Why?
|
Genes, Immunoglobulin | 1 | 2011 | 285 | 0.020 |
Why?
|
Osteonecrosis | 1 | 2013 | 229 | 0.020 |
Why?
|
Transplantation Conditioning | 1 | 1998 | 1590 | 0.020 |
Why?
|
Hepatocyte Growth Factor | 1 | 2012 | 270 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 2013 | 13446 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 26125 | 0.020 |
Why?
|
Infusions, Intravenous | 2 | 2012 | 2219 | 0.020 |
Why?
|
Luminescent Measurements | 1 | 2012 | 342 | 0.020 |
Why?
|
Sampling Studies | 1 | 1992 | 615 | 0.020 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 1996 | 851 | 0.020 |
Why?
|
Pneumonectomy | 1 | 2017 | 1119 | 0.020 |
Why?
|
Leukemia | 3 | 1989 | 1522 | 0.020 |
Why?
|
Phthalazines | 1 | 2013 | 383 | 0.020 |
Why?
|
Nomograms | 1 | 2012 | 230 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 2015 | 1125 | 0.020 |
Why?
|
Larva | 1 | 2012 | 508 | 0.020 |
Why?
|
Nausea | 1 | 2013 | 679 | 0.020 |
Why?
|
HLA-D Antigens | 2 | 1987 | 129 | 0.020 |
Why?
|
Apoptosis | 2 | 2020 | 9486 | 0.020 |
Why?
|
Probability | 2 | 1993 | 2477 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3882 | 0.020 |
Why?
|
Multicenter Studies as Topic | 2 | 1992 | 1702 | 0.020 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 664 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2013 | 17635 | 0.020 |
Why?
|
Taxoids | 1 | 2013 | 668 | 0.020 |
Why?
|
Colitis, Ulcerative | 1 | 2022 | 1922 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2024 | 4486 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 2850 | 0.020 |
Why?
|
Crohn Disease | 1 | 2022 | 2279 | 0.020 |
Why?
|
Zinc Fingers | 1 | 2011 | 579 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 899 | 0.020 |
Why?
|
Hyperplasia | 1 | 2012 | 1152 | 0.020 |
Why?
|
Withholding Treatment | 1 | 2013 | 617 | 0.020 |
Why?
|
Alleles | 2 | 2010 | 6863 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2022 | 3415 | 0.020 |
Why?
|
Mycosis Fungoides | 1 | 1990 | 170 | 0.020 |
Why?
|
Ligands | 1 | 2015 | 3272 | 0.020 |
Why?
|
Medication Adherence | 1 | 2020 | 2176 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2013 | 877 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2013 | 2748 | 0.020 |
Why?
|
Epidemiologic Methods | 2 | 2011 | 1336 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2023 | 4016 | 0.020 |
Why?
|
Curriculum | 1 | 2022 | 3743 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 2013 | 1129 | 0.020 |
Why?
|
HLA-DR Antigens | 2 | 1987 | 602 | 0.020 |
Why?
|
Oligodendroglia | 1 | 2012 | 538 | 0.020 |
Why?
|
Myelin Sheath | 1 | 2012 | 653 | 0.020 |
Why?
|
SEER Program | 1 | 2013 | 1450 | 0.020 |
Why?
|
Pain | 1 | 2023 | 5073 | 0.020 |
Why?
|
Vitamin D | 1 | 2022 | 3303 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2018 | 12341 | 0.020 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1222 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2013 | 1784 | 0.020 |
Why?
|
Area Under Curve | 1 | 2012 | 1638 | 0.020 |
Why?
|
Hospital Mortality | 2 | 2013 | 5294 | 0.020 |
Why?
|
Reoperation | 2 | 2008 | 4303 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2024 | 3808 | 0.020 |
Why?
|
Databases as Topic | 1 | 2009 | 473 | 0.020 |
Why?
|
Microscopy, Immunoelectron | 1 | 2007 | 317 | 0.020 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2009 | 592 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2011 | 1900 | 0.020 |
Why?
|
E-Selectin | 1 | 2009 | 576 | 0.020 |
Why?
|
Gene Rearrangement, T-Lymphocyte | 1 | 2007 | 111 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3416 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1844 | 0.020 |
Why?
|
Living Donors | 1 | 2011 | 641 | 0.020 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2009 | 691 | 0.020 |
Why?
|
DNA Primers | 1 | 2011 | 2819 | 0.020 |
Why?
|
Azathioprine | 1 | 1988 | 354 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14605 | 0.020 |
Why?
|
Leprosy | 1 | 1987 | 126 | 0.020 |
Why?
|
Tamoxifen | 1 | 2011 | 965 | 0.020 |
Why?
|
Multigene Family | 1 | 2010 | 1076 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1990 | 646 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2019 | 9539 | 0.020 |
Why?
|
Diarrhea | 1 | 2013 | 1318 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2012 | 3597 | 0.020 |
Why?
|
Animals, Genetically Modified | 1 | 2011 | 1561 | 0.020 |
Why?
|
Esophagus | 1 | 2012 | 1033 | 0.020 |
Why?
|
Family Health | 1 | 2011 | 1257 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 2011 | 4174 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2016 | 2057 | 0.020 |
Why?
|
Translocation, Genetic | 1 | 2011 | 1393 | 0.020 |
Why?
|
Zebrafish Proteins | 1 | 2012 | 1014 | 0.020 |
Why?
|
Thromboembolism | 1 | 2012 | 995 | 0.020 |
Why?
|
Mice, Nude | 1 | 2011 | 3615 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2013 | 3595 | 0.020 |
Why?
|
Administration, Oral | 1 | 2013 | 4021 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1779 | 0.020 |
Why?
|
Pilot Projects | 2 | 2001 | 8631 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2008 | 1096 | 0.020 |
Why?
|
Receptors, Estrogen | 1 | 2013 | 2208 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2007 | 15631 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2011 | 1440 | 0.020 |
Why?
|
Age Distribution | 1 | 2011 | 2880 | 0.020 |
Why?
|
Chimera | 1 | 1986 | 453 | 0.010 |
Why?
|
Kinetics | 1 | 2012 | 6374 | 0.010 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 3204 | 0.010 |
Why?
|
Ventricular Remodeling | 1 | 2012 | 1267 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5336 | 0.010 |
Why?
|
World Health Organization | 1 | 2010 | 1322 | 0.010 |
Why?
|
Pandemics | 1 | 2024 | 8654 | 0.010 |
Why?
|
Intestinal Mucosa | 1 | 1995 | 3032 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2015 | 2827 | 0.010 |
Why?
|
Tachycardia, Ventricular | 1 | 1992 | 1304 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2016 | 4511 | 0.010 |
Why?
|
Up-Regulation | 1 | 2012 | 4124 | 0.010 |
Why?
|
RNA Interference | 1 | 2011 | 2831 | 0.010 |
Why?
|
Learning | 1 | 2012 | 1740 | 0.010 |
Why?
|
Piperazines | 1 | 2013 | 2523 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3429 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 1985 | 11118 | 0.010 |
Why?
|
Motor Activity | 1 | 2012 | 2715 | 0.010 |
Why?
|
Antilymphocyte Serum | 1 | 1984 | 487 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2007 | 1008 | 0.010 |
Why?
|
Patient Compliance | 1 | 2012 | 2690 | 0.010 |
Why?
|
Evaluation Studies as Topic | 2 | 2000 | 1624 | 0.010 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 2047 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2012 | 22169 | 0.010 |
Why?
|
Stents | 1 | 2013 | 3179 | 0.010 |
Why?
|
Coronary Disease | 1 | 1996 | 5914 | 0.010 |
Why?
|
Hospitals, Special | 1 | 1982 | 91 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3778 | 0.010 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2007 | 1133 | 0.010 |
Why?
|
Odds Ratio | 1 | 2013 | 9646 | 0.010 |
Why?
|
Transplantation, Autologous | 2 | 1998 | 2115 | 0.010 |
Why?
|
Pregnancy | 1 | 2022 | 29874 | 0.010 |
Why?
|
Fractures, Bone | 1 | 2013 | 2046 | 0.010 |
Why?
|
Diabetes Complications | 1 | 2007 | 1315 | 0.010 |
Why?
|
Escherichia coli | 1 | 2013 | 4217 | 0.010 |
Why?
|
Leukocytosis | 1 | 2001 | 251 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2012 | 3826 | 0.010 |
Why?
|
Critical Illness | 1 | 2013 | 2723 | 0.010 |
Why?
|
Transplantation, Homologous | 3 | 2000 | 4806 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17904 | 0.010 |
Why?
|
Radiotherapy Dosage | 2 | 1998 | 2898 | 0.010 |
Why?
|
Genetic Diseases, Inborn | 1 | 1984 | 604 | 0.010 |
Why?
|
Stem Cells | 1 | 2012 | 3522 | 0.010 |
Why?
|
Antigens, CD | 1 | 2010 | 4003 | 0.010 |
Why?
|
Risk | 3 | 1987 | 9610 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 1994 | 5796 | 0.010 |
Why?
|
Population Surveillance | 1 | 2009 | 2598 | 0.010 |
Why?
|
Nuclear Family | 1 | 2000 | 311 | 0.010 |
Why?
|
Genetic Linkage | 1 | 1984 | 2341 | 0.010 |
Why?
|
Platelet Count | 1 | 2001 | 781 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2009 | 3492 | 0.010 |
Why?
|
Carmustine | 1 | 1998 | 138 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2007 | 2547 | 0.010 |
Why?
|
Prevalence | 1 | 2015 | 15732 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2007 | 6534 | 0.010 |
Why?
|
DNA Methylation | 1 | 2011 | 4398 | 0.010 |
Why?
|
Korea | 2 | 1987 | 98 | 0.010 |
Why?
|
Patient Dropouts | 1 | 1999 | 412 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2014 | 15842 | 0.010 |
Why?
|
Length of Stay | 1 | 2009 | 6425 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2007 | 3673 | 0.010 |
Why?
|
Protein Binding | 1 | 2007 | 9351 | 0.010 |
Why?
|
Anticoagulants | 1 | 2011 | 4812 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 1996 | 11460 | 0.010 |
Why?
|
Syndrome | 1 | 2001 | 3267 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2012 | 22176 | 0.010 |
Why?
|
Behavior Therapy | 1 | 2000 | 879 | 0.010 |
Why?
|
Cause of Death | 2 | 1998 | 3683 | 0.010 |
Why?
|
Clinical Competence | 1 | 2009 | 4792 | 0.010 |
Why?
|
Aging | 1 | 1993 | 8708 | 0.010 |
Why?
|
Levamisole | 1 | 1993 | 35 | 0.010 |
Why?
|
Graft Rejection | 1 | 1986 | 4445 | 0.010 |
Why?
|
Mathematics | 1 | 1993 | 707 | 0.010 |
Why?
|
Ki-67 Antigen | 1 | 1994 | 629 | 0.010 |
Why?
|
Pulmonary Wedge Pressure | 1 | 1992 | 273 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 1985 | 7827 | 0.010 |
Why?
|
Salvage Therapy | 1 | 1998 | 1264 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 2001 | 1666 | 0.010 |
Why?
|
Heart Failure | 1 | 2015 | 11669 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2010 | 12690 | 0.010 |
Why?
|
BCG Vaccine | 1 | 1993 | 369 | 0.010 |
Why?
|
Tissue Donors | 1 | 2000 | 2331 | 0.010 |
Why?
|
Anthracenes | 1 | 1989 | 83 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 2273 | 0.010 |
Why?
|
Mitoguazone | 1 | 1989 | 11 | 0.010 |
Why?
|
Vinblastine | 1 | 1991 | 488 | 0.010 |
Why?
|
Mitoxantrone | 1 | 1989 | 148 | 0.010 |
Why?
|
Southwestern United States | 1 | 1989 | 39 | 0.010 |
Why?
|
L-Lactate Dehydrogenase | 1 | 1990 | 411 | 0.010 |
Why?
|
Drug Therapy, Combination | 2 | 1988 | 6310 | 0.000 |
Why?
|
Electrocardiography | 1 | 2001 | 6377 | 0.000 |
Why?
|
Hematologic Neoplasms | 1 | 2000 | 1896 | 0.000 |
Why?
|
Lepromin | 1 | 1987 | 8 | 0.000 |
Why?
|
Analysis of Variance | 1 | 1996 | 6228 | 0.000 |
Why?
|
Regression Analysis | 2 | 1989 | 6343 | 0.000 |
Why?
|
Cardiopulmonary Bypass | 1 | 1992 | 1092 | 0.000 |
Why?
|
Lactoylglutathione Lyase | 1 | 1986 | 7 | 0.000 |
Why?
|
Complement C2 | 1 | 1986 | 46 | 0.000 |
Why?
|
Preoperative Care | 1 | 1996 | 2242 | 0.000 |
Why?
|
Acute Disease | 2 | 1989 | 7237 | 0.000 |
Why?
|
Cell Division | 1 | 1994 | 4465 | 0.000 |
Why?
|
Leukocyte Count | 1 | 1990 | 1596 | 0.000 |
Why?
|
HLA-DQ Antigens | 1 | 1986 | 191 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 1984 | 10194 | 0.000 |
Why?
|
Complement C4 | 1 | 1986 | 217 | 0.000 |
Why?
|
Oxymetholone | 1 | 1984 | 9 | 0.000 |
Why?
|
Procarbazine | 1 | 1983 | 172 | 0.000 |
Why?
|
Colony-Forming Units Assay | 1 | 1984 | 352 | 0.000 |
Why?
|
Random Allocation | 1 | 1984 | 2395 | 0.000 |
Why?
|
Disease Susceptibility | 1 | 1987 | 1787 | 0.000 |
Why?
|
Postoperative Period | 1 | 1985 | 1813 | 0.000 |
Why?
|
Blood Transfusion | 1 | 1986 | 1298 | 0.000 |
Why?
|
Hematopoiesis | 1 | 1986 | 2049 | 0.000 |
Why?
|
Androgens | 1 | 1984 | 1286 | 0.000 |
Why?
|
Carcinoma in Situ | 1 | 1982 | 791 | 0.000 |
Why?
|
Glucocorticoids | 1 | 1985 | 2161 | 0.000 |
Why?
|
Genetic Testing | 1 | 1986 | 3537 | 0.000 |
Why?
|
Phenotype | 1 | 1989 | 16591 | 0.000 |
Why?
|